The rapidly evolving primary care market and the growing influence of managed care add interesting wrinkles to the US market debut of Ironwood Pharmaceutical Inc.’s constipation drug Linzess (linaclotide).
The once-daily oral drug received FDA approval on August 30 for chronic idiopathic constipation and irritable bowel syndrome with constipation (IBS-C) and for relief of pain associated with constipation, and...